XOMA Corporation (Nasdaq: XOMA) announced it has initiated its proof-of-concept study to evaluate the safety and clinical pharmacology of a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE